Ductal carcinoma is a breast cancer that can be either invasive or in situ (inside).
Learn more about breast cancer from UPMC Hillman Cancer Center.
Ductal carcinoma in situ (Stage 0) is the most common non-invasive breast cancer, where abnormal cells have been contained in the lining of the breast milk duct.
Invasive ductal carcinoma, the most common type of breast cancer, occurs when mutated cells spread from the milk ducts into the breast tissue. It can also metastasize and affect other parts of the body if left untreated.
Never Miss a Beat!
Subscribe to Our HealthBeat Newsletter!
Get Healthy Tips Sent to Your Phone!
Ductal Carcinoma Risk Factors
Although anyone can develop this type of cancer, the following factors are known to increase your risk:
- Family history of breast cancer and ovarian cancer
- Over 50 years of age
- No pregnancy before age 30
- First period before the age of 12
- Not breastfeeding after pregnancy
You might also like…
Symptoms of Ductal Carcinoma
There are warning signs that could be symptoms of ductal carcinoma:
- Changes in the breast, such as in the size or shape
- A hard lump that doesn’t move freely
- Fluid, especially bloody fluid, from the nipple (other than breast milk)
- Red, swollen, dimpled, or puckered skin on the breast, nipple, or areola
- A nipple that turns inward
If you notice any of these symptoms, make an appointment with your doctor.
Treatment Options for Ductal Carcinoma
As with all cancer, your doctor and health care team will work with you on the best treatment options based on your current health and test results. Treatment may include hormone therapy, radiation therapy, or chemotherapy, as well as several forms of surgery such as:
- Sentinel lymph node biopsy
- Axillary lymph node dissection
UPMC Hillman Cancer Center provides world-class cancer care, from diagnosis to treatment, to help you in your cancer battle. We are the only comprehensive cancer center in our region, as designated by the National Cancer Institute. We have more than 70 locations throughout Pennsylvania, Ohio, New York, and Maryland, with more than 200 oncologists. Our internationally renowned research team is striving to find new advances in prevention, detection, and treatment.